文献速递神经核医学肿瘤 PET/CT

DTI-ALPS指数评估的类淋巴功能障碍通过淀粉样蛋白β依赖通路介导阿尔茨海默病认知下降:多模态PET/MRI研究

DTI-ALPS index-assessed glymphatic dysfunction mediates Alzheimer's cognitive decline via amyloid-β-dependent pathways: multimodal PET/MRI study.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2025-07-18

本回顾性研究纳入140例受试者(99例阿尔茨海默病、35例轻度认知障碍、6例主观认知下降),采用三示踪剂PET/MRI及DTI-ALPS指数评估类淋巴功能。ALPS指数随临床分期进展而降低,淀粉样蛋白β-PET完全介导ALPS对FDG-PET和认知的影响,且不依赖tau蛋白。早发型与晚发型阿尔茨海默病的ALPS-认知关系不同。

要点

  • ALPS指数随临床阶段进展而降低:主观认知下降1.51±0.08、轻度认知障碍1.37±0.13、阿尔茨海默病1.32±0.14(P=0.001)。
  • 淀粉样蛋白β-PET完全介导ALPS对FDG-PET(β=-0.14,P=0.002)和认知(β=0.12~0.14,P<0.01)的影响,不依赖tau(P>0.05)。
  • 早发型与晚发型阿尔茨海默病的ALPS-认知关系不同(MMSE:r=-0.39,P=0.016 vs ρ=-0.06,P=0.620)。

核心结论

  • DTI-ALPS可量化类淋巴功能障碍,该障碍主要通过淀粉样蛋白β依赖通路驱动阿尔茨海默病进展,早发型阿尔茨海默病表现出与晚发型不同的神经影像-认知关系。

研究设计与样本

  • 本回顾性研究(2021-2024年)分析140例参与者,中位年龄69.00(61.00,74.00)岁,其中女性84例,包括99例阿尔茨海默病(37例早发型、62例晚发型)、35例轻度认知障碍和6例主观认知下降。
  • 所有参与者接受同步[18F]Florbetapir(淀粉样蛋白β)、[18F]PI-2620(tau)和[18F]FDG PET/MRI,并用DTI-ALPS指数定量类淋巴功能。
  • 采用因果中介分析评估生物标志物间关系(P<0.05)。

主要发现

  • ALPS指数随临床阶段进展而降低:主观认知下降1.51±0.08 vs 轻度认知障碍1.37±0.13 vs 阿尔茨海默病1.32±0.14(P=0.001)。
  • ALPS指数与较高淀粉样蛋白β-PET(r=-0.31,P<0.001)、tau-PET(ρ=-0.18,P=0.035)和FDG-PET评分(ρ=-0.22,P=0.008)相关。
  • 淀粉样蛋白β-PET完全介导ALPS对FDG-PET(β=-0.14,P=0.002)和认知(β=0.12~0.14,P<0.01)的影响,独立于tau(P>0.05)。
  • 淀粉样蛋白β阴性亚组显示ALPS与年龄(r=-0.48,P=0.007)、教育(r=0.39,P=0.035)和认知(MoCA:r=0.62,P<0.001)相关。
  • 淀粉样蛋白β阳性亚组显示ALPS与淀粉样蛋白β负相关(ρ=-0.27,P=0.010;年龄/教育校正后ρ=-0.24,P=0.022),并与认知正相关(MMSE:ρ=0.28,P=0.009)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The role of glymphatic dysfunction in Alzheimer's disease (AD), as measured by diffusion tensor imaging along perivascular spaces (DTI-ALPS) indexing of perivascular function, its progression, and its interaction with amyloid-β (Aβ) and tau proteins, remains controversial. To investigate whether the DTI-ALPS index mediates AD-related cognitive decline through Aβ/tau-dependent pathways using tri-tracer PET/MRI. METHODS: This retrospective study (2021-2024) analyzed 140 participants (median age 69.00 [61.00, 74.00] years; 84 women), including 99 with AD (37 early-onset [EOAD], 62 late-onset [LOAD]), 35 with mild cognitive impairment (MCI), and 6 with subjective cognitive decline (SCD). All participants underwent simultaneous [1⁸F] Florbetapir (Aβ), [1⁸F] PI-2620(tau), and [1⁸F] FDG PET/MRI with DTI-ALPS indexing for glymphatic function quantification. Causal mediation analysis was used to assess the relationships between biomarkers (P < 0.05). RESULTS: The ALPS index progressively decreased across clinical stages (SCD: 1.51 ± 0.08 vs. MCI: 1.37 ± 0.13 vs. AD: 1.32 ± 0.14; P = 0.001), correlating with higher Aβ-PET (r = - 0.31, P < 0.001), tau-PET (ρ = - 0.18, P = 0.035), and FDG-PET scores (ρ = - 0.22, P = 0.008). Aβ-PET fully mediated the ALPS effects on FDG-PET (β = - 0.14, P = 0.002) and cognition (β = 0.12 ~ 0.14, P < 0.01), independent of tau (P > 0.05). The Aβ-negative subgroups showed correlations with ALPS-age (r = - 0.48, P = 0.007), ALPS-education (r = 0.39, P = 0.035), and ALPS-cognition (MoCA: r = 0.62, P < 0.001). The Aβ-positive subgroups revealed inverse ALPS-Aβ associations (ρ = - 0.27, P = 0.010; age/education-adjusted ρ = - 0.24, P = 0.022) alongside positive adjusted correlations with cognition (MMSE: ρ = 0.28, P = 0.009). EOAD exhibited distinct ALPS-cognition relationships compared to LOAD (MMSE: r = - 0.39, P = 0.016 vs. ρ = - 0.06, P = 0.620). CONCLUSION: DTI-ALPS quantifies glymphatic dysfunction driving AD progression predominantly through Aβ-dependent pathways, with EOAD demonstrating distinct neuroimaging-cognition relationships compared to LOAD.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Zhang Y, Huang G, Geng J, et al. DTI-ALPS index-assessed glymphatic dysfunction mediates Alzheimer's cognitive decline via amyloid-β-dependent pathways: multimodal PET/MRI study. Eur J Nucl Med Mol Imaging. 2025. PMID: 40679601. doi:10.1007/s00259-025-07445-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。